This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Rockwell Medical (RMTI) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Rockwell Medical (RMTI) delivered earnings and revenue surprises of 125% and 12.26%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Jushi Holdings Inc. (JUSHF) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Jushi Holdings Inc. (JUSHF) delivered earnings and revenue surprises of 83.33% and 3.81%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
TG Therapeutics (TGTX) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
TG Therapeutics (TGTX) delivered earnings and revenue surprises of 200% and 11.12%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Evolus (EOLS) delivered earnings and revenue surprises of -75% and 2.85%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Rockwell Medical (RMTI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rockwell Medical (RMTI) delivered earnings and revenue surprises of 60% and 7.06%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
InMode (INMD) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
InMode (INMD) delivered earnings and revenue surprises of 12.50% and 0.23%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Rockwell Medical (RMTI) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
In the latest trading session, Rockwell Medical (RMTI) closed at $1.65, marking a +1.85% move from the previous day.
Rockwell Medical (RMTI) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Rockwell Medical (RMTI) delivered earnings and revenue surprises of 125% and 0.01%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Rockwell Medical (RMTI) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
Rockwell Medical (RMTI) concluded the recent trading session at $1.54, signifying a +1.32% move from its prior day's close.
Rockwell Medical (RMTI) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
In the closing of the recent trading day, Rockwell Medical (RMTI) stood at $1.48, denoting a +0.68% change from the preceding trading day.
Rockwell Medical (RMTI) Flat As Market Gains: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Rockwell Medical (RMTI) stood at $1.37, denoting no change from the preceding trading day.
Why Rockwell Medical (RMTI) Dipped More Than Broader Market Today
by Zacks Equity Research
In the closing of the recent trading day, Rockwell Medical (RMTI) stood at $1.34, denoting a -0.74% change from the preceding trading day.
Rockwell Medical (RMTI) Flat As Market Gains: What You Should Know
by Zacks Equity Research
Rockwell Medical (RMTI) closed at $1.29 in the latest trading session, marking no change from the prior day.
Rockwell Medical (RMTI) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rockwell Medical (RMTI) delivered earnings and revenue surprises of 41.67% and 0.43%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Why Rockwell Medical (RMTI) Outpaced the Stock Market Today
by Zacks Equity Research
Rockwell Medical (RMTI) closed the most recent trading day at $1.95, moving +1.04% from the previous trading session.
Rockwell Medical (RMTI) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
The latest trading day saw Rockwell Medical (RMTI) settling at $1.58, representing a -1.25% change from its previous close.
Rockwell Medical (RMTI) Stock Moves -1.18%: What You Should Know
by Zacks Equity Research
Rockwell Medical (RMTI) closed at $1.68 in the latest trading session, marking a -1.18% move from the prior day.
Why Rockwell Medical (RMTI) Dipped More Than Broader Market Today
by Zacks Equity Research
The latest trading day saw Rockwell Medical (RMTI) settling at $1.97, representing a -0.51% change from its previous close.
Rockwell Medical (RMTI) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Rockwell Medical (RMTI) closed at $2.06 in the latest trading session, marking a +1.48% move from the prior day.
Rockwell Medical (RMTI) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Rockwell Medical (RMTI) closed at $1.85, marking a +1.09% move from the previous day.
Rockwell Medical (RMTI) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Rockwell Medical (RMTI) closed the most recent trading day at $1.92, moving +1.05% from the previous trading session.
Rockwell Medical (RMTI) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Robust product demand and cost-saving initiatives are likely to have boosted Rockwell Medical's (RMTI) second quarter's top line.
Leafly Holdings, Inc. (LFLY) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Leafly Holdings, Inc. (LFLY) delivered earnings and revenue surprises of 55.56% and 1.35%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Cresco Labs Inc. (CRLBF) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Cresco Labs Inc. (CRLBF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PetIQ (PETQ) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
PetIQ (PETQ) delivered earnings and revenue surprises of 76.92% and 14.72%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?